VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

Korábbi kezelés

• Has evidence of erythrodermic, pustular, predominantly inverse or guttate psoriasis, or drug-induced psoriasis.
• Has used any topical medication that could affect psoriasis (including corticosteroids, retinoids, vitamin D analogues [such as calcipotriol], Janus kinase [JAK] inhibitors, or tar) within 2 weeks prior to Day 1.
• Has used any systemic treatment that could affect psoriasis (including corticosteroids, oral retinoids, immunosuppressive medication, anakinra, methotrexate, cyclosporine, oral JAK inhibitors, or apremilast) within 4 weeks prior to Day 1.
  • Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed.
• Participant has received any ultraviolet B (UVB) phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day 1.
• Participant has had psoralen and ultraviolet A (PUVA) treatment within 4 weeks prior to Day 1.
• Participant has received treatment with an investigational or marketed TYK2 inhibitor.

Más betegség

• History of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
• Has immune-mediated conditions commonly associated with psoriasis, such as psoriatic arthritis, active uveitis, inflammatory bowel disease, that currently require systemic treatment (including corticosteroids, immunosuppressants, or biologics).
  • Note: Participants with immune-mediated conditions commonly associated with psoriasis that do not require systemic treatment may be included in the study.

Egyéb

• Female who is breastfeeding, pregnant, lactating, or who is planning to become pregnant during the study.
• Participant is known to have immune deficiency or is immunocompromised.

• Male or female participant aged 18 years or older.
• History of primarily plaque psoriasis for at least 6 months prior to the screening visit.
• Has had stable psoriasis conditions for at least 3 months before screening.
• Has moderate to severe plaque psoriasis as defined by a PASI score of ≥ 12 and an sPGA score of ≥ 3 at screening and Day 1.
• Has plaque psoriasis covering ≥ 10% of the total BSA at screening and Day 1.
• Deemed by the investigator to be eligible for phototherapy or systemic therapy.
• Females of childbearing potential must agree to use a highly effective contraceptive method from at least 4 weeks prior to Day 1 until at least 4 weeks after the last dose of study product.